TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases

Pediatric Blood and Cancer

Volumn 56, Issue 2, 2011, Pages 217-225

  Zaliova, Marketa ^a   Meyer, Claus ^b   Cario, Gunnar ^c   Vaskova, Martina ^a   Marschalek, Rolf ^b   Stary, Jan ^a   Zuna, Jan ^a   Trka, Jan ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Acute lymphoblastic leukemia; Childhood leukemia; TEL AML1

Indexed keywords

HELIX LOOP HELIX PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME BREAKAGE; CLINICAL FEATURE; EXON; FUSION GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE REPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INTRON; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN DOMAIN; REPORTER GENE; TEL AML1 FUSION GENE; TREATMENT RESPONSE;

ADOLESCENT; BASE SEQUENCE; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; EXONS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78650158554     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22686     Document Type: Article

References (47)

1. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-1989.
2. Romana SP, Poirel H, Leconiat M, et al. High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 1995; 86: 4263-4269.
3. Golub TR, Barker GF, Bohlander SK, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917-4921.
4. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252-4258.
5. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997; 90: 571-577.
6. Romana SP, Mauchauffe M, Le Coniat M, et al. The t(12;21) of acute lymphoblastic leukemia results in a TEL-AML1 gene fusion. Blood 1995; 85: 3662-3670.
7. Wiemels JL, Greaves M. Structure and possible mechanisms of TEL-AML1 gene fusions in childhood acute lymphoblastic leukemia. Cancer Res 1999; 59: 4075-4082.
8. Wiemels JL, Alexander FE, Cazzaniga G, et al. Microclustering of TEL-AML1 translocation breakpoints in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 2000; 29: 219-228.
9. Andersen MT, Nordentoft I, Hjalgrim LL, et al. Characterization of t(12;21) breakpoint junctions in acute lymphoblastic leukemia. Leukemia 2001; 15: 858-859.
10. Bohlander SK. ETV6: A versatile player in leukemogenesis. Semin Cancer Biol 2005; 15: 162-174.
11. Blyth K, Cameron ER, Neil JC. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer 2005; 5: 376-387.
12. Wang LC, Swat W, Fujiwara Y, et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev 1998; 12: 2392-2402.
13. Hock H, Meade E, Medeiros S, et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev 2004; 18: 2336-2341.
14. Wang Q, Stacy T, Binder M, et al. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996; 93: 3444-3449.
15. Okuda T, van Deursen J, Hiebert SW, et al. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-330.
16. Silva FP, Morolli B, Storlazzi CT, et al. Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene 2003; 22: 538-547.
17. Fenrick R, Wang L, Nip J, et al. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Mol Cell Biol 2000; 20: 5828-5839.
18. Sabaawy HE, Azuma M, Embree LJ, et al. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006; 103: 15166-15171.
19. Bernardin F, Yang Y, Cleaves R, et al. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res 2002; 62: 3904-3908.
20. Andreasson P, Schwaller J, Anastasiadou E, et al. The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genet Cytogenet 2001; 130: 93-104.
21. Tsuzuki S, Seto M, Greaves M, et al. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice. Proc Natl Acad Sci USA 2004; 101: 8443-8448.
22. Morrow M, Horton S, Kioussis D, et al. TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood 2004; 103: 3890-3896.
23. Fischer M, Schwieger M, Horn S, et al. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Oncogene 2005; 24: 7579-7591.
24. Morrow M, Samanta A, Kioussis D, et al. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene 2007; 26: 4404-4414.
25. Zelent A, Greaves M, Enver T. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 2004; 23: 4275-4283.
26. Uchida H, Downing JR, Miyazaki Y, et al. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene 1999; 18: 1015-1022.
27. Starkova J, Madzo J, Cario G, et al. The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells. Clin Cancer Res 2007; 13: 1726-1735.
28. Hiebert SW, Sun W, Davis JN, et al. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 1996; 16: 1349-1355.
29. Guidez F, Petrie K, Ford AM, et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. Blood 2000; 96: 2557-2561.
30. Fenrick R, Amann JM, Lutterbach B, et al. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol 1999; 19: 6566-6574.
31. Fears S, Gavin M, Zhang DE, et al. Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter. Proc Natl Acad Sci USA 1997; 94: 1949-1954.
32. Rho JK, Kim JH, Yu J, et al. Correlation between cellular localization of TEL/AML1 fusion protein and repression of AML1-mediated transactivation of CR1 gene. Biochem Biophys Res Commun 2002; 297: 91-95.
33. Lee YJ, Kim JH, Bae S, et al. Mechanism of transcriptional repression by TEL/RUNX1 fusion protein. Mol Cells 2004; 17: 217-222.
34. Gunji H, Waga K, Nakamura F, et al. TEL/AML1 shows dominant-negative effects over TEL as well as AML1. Biochem Biophys Res Commun 2004; 322: 623-630.
35. Schindler JW, Van Buren D, Foudi A, et al. TEL-AML1 corrupts hematopoietic stem cells to persist in the bone marrow and initiate leukemia. Cell Stem Cell 2009; 5: 43-53.
36. Lopez RG, Carron C, Oury C, et al. TEL is a sequence-specific transcriptional repressor. J Biol Chem 1999; 274: 30132-30138.
37. Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005; 105: 821-826.
38. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.
39. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 2004; 103: 1043-1049.
40. van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
41. Nakao M, Yokota S, Horiike S, et al. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 1463-1470.
42. Vaskova M, Mejstrikova E, Kalina T, et al. Transfer of genomics information to flow cytometry: Expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia. Leukemia 2005; 19: 876-878.
43. Wang L, Hiebert SW. TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. Oncogene 2001; 20: 3716-3725.
44. Chakrabarti SR, Nucifora G. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. Biochem Biophys Res Commun 1999; 264: 871-877.
45. Million RP, Harakawa N, Roumiantsev S, et al. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol 2004; 24: 4685-4695.
46. Eguchi M, Eguchi-Ishimae M, Green A, et al. Directing oncogenic fusion genes into stem cells via an SCL enhancer. Proc Natl Acad Sci USA 2005; 102: 1133-1138.
47. Yan M, Burel SA, Peterson LF, et al. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci USA 2004; 101: 17186-17191.